Table 2.
TZP resistance | Blood | Pus swab | Stool | Urine | Total |
---|---|---|---|---|---|
N (%col) | N (%col) | N (%col) | N (%col) | N (%col) | |
R | 10 (66.7%) |
6 (60%) |
52 (73.2%) |
34 (35.1%) |
102 (52.9%) |
I | 2 (13.3%) |
3 (30%) |
9 (12.7%) |
38 (39.2%) |
52 (26.9%) |
S | 3 (20%) |
1 (10%) |
10 (14.1%) |
25 (25.8%) |
39 (20.2%) |
Total | 15 (100%) |
10 (100%) |
71 (100%) |
97 (100%) |
193* (100%) |
Chi-square = 27.17 with 6 df; p = 0.0001 | |||||
CAZ resistance | Blood | Pus swab | Stool | Urine | Total |
N (%col) | N (%col) | N (%col) | N (%col) | N (%col) | |
R | 15 (100%) |
10 (100%) |
63 (88.7%) |
60 (61.9%) |
148 (76.7%) |
I | 0 (0%) |
0 (0%) |
2 (2.82%) |
13 (13.4%) |
15 (7.77%) |
S | 0 (0%) |
0 (0%) |
6 (8.45%) |
24 (24.7%) |
30 (15.5%) |
Total | 15 (100%) |
10 (100%) |
71 (100%) |
97 (100%) |
193* (100%) |
Chi-square = 25.50 with 6 df; p = 0.0003 |
Distribution of piperacillin/tazobactam (TZP) and ceftazidime (CAZ) resistance phenotypes according to site of isolation. Phenotype-phenotype associations are tested by Chi-square test for independence. %col = percentage of column total.
*The total N = 193 after exclusion of tissues from which two or fewer samples were isolated.